Streetbeat News

Analyst Ratings

ARGX

Raymond James analyst Danielle Brill maintains a Strong Buy rating on argenx (NASDAQ:ARGX) and raises the price target from $460 to $600.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:21 am

MUSA

Raymond James analyst Bobby Griffin maintains an Outperform rating on Murphy USA (NYSE:MUSA) and raises the price target from $315 to $350.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:19 am

MIRM

Raymond James analyst Steven Seedhouse has maintained a Strong Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raised the price target from $81 to $82.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:16 am

ARQT

Needham analyst Serge Belanger has reiterated a 'Buy' rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and maintained a price target of $24.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:14 am

IVVD

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Invivyd (NASDAQ:IVVD) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:13 am

ARGX

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on argenx (NASDAQ:ARGX) and maintained a price target of $494.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:12 am

MRUS

EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on Merus (NASDAQ:MRUS) and maintained a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:10 am

COYA

EF Hutton analyst Elemer Piros has reiterated a 'Buy' rating on Coya Therapeutics (NASDAQ:COYA) and maintained a $28 price target.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:08 am

ALLT

Needham analyst Alex Henderson has maintained a 'Buy' rating on Allot (NASDAQ:ALLT) but lowered the price target from $4.5 to $4.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:08 am

BLK

TSLA

CNBC's Jim Cramer emphasized the importance of portfolio diversification, comparing the investment strategies of ARK's Cathie Wood and BlackRock's Larry Fink. Wood's high-risk strategy focuses on a few high-potential stocks, leading to significant gains and losses. Fink's strategy prioritizes diversification across different sectors and factors influencing inflation.

Portfolio Pulse from Benzinga Neuro

July 18, 2023 | 8:00 am